Randomized Trial of Tenofovir Versus Lamivudine Plus Adefovir in Lamivudine Plus Adefovir Treated Lamivudine-resistant Chronic Hepatitis B Patients With Undetectable Hepatitis B Virus DNA.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Tenofovir disoproxil fumarate (Primary) ; Adefovir dipivoxil; Lamivudine
Indications Hepatitis B
Focus Therapeutic Use

27 Oct 2016 Status changed from active, no longer recruiting to completed.
15 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Apr 2016, according to ClinicalTrials.gov record.
15 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com